HC Wainwright Reaffirms "Sell" Rating for Sarepta Therapeutics (NASDAQ:SRPT)

Key Points

• Sarepta Therapeutics has received a "Sell" rating from HC Wainwright, indicating a negative outlook for the stock amidst varying sentiments from other analysts.
• The company's stock has a current average rating of "Hold" with a consensus price target of $43.50, despite having a volatile performance with a high of $143.49 and a low of $10.41 over the past year.
• Sarepta Therapeutics reported a significant 68.4% increase in quarterly revenue year-over-year, reaching $611.09 million, alongside positive earnings results that exceeded consensus estimates.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report)'s stock had its "sell" rating reaffirmed by HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports.

SRPT has been the topic of several other research reports. Cantor Fitzgerald reaffirmed a "neutral" rating on shares of Sarepta Therapeutics in a report on Monday, June 16th. Deutsche Bank Aktiengesellschaft upped their price target on shares of Sarepta Therapeutics to $12.00 and gave the company a "sell" rating in a report on Friday, August 15th. Robert W. Baird upped their price target on shares of Sarepta Therapeutics from $30.00 to $35.00 and gave the company an "outperform" rating in a report on Thursday, July 17th. Barclays raised shares of Sarepta Therapeutics from an "underweight" rating to an "equal weight" rating and set a $22.00 price target on the stock in a report on Tuesday, July 29th. Finally, Baird R W downgraded shares of Sarepta Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Friday, July 18th. Eight investment analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and six have assigned a Sell rating to the company. According to data from MarketBeat, Sarepta Therapeutics currently has an average rating of "Hold" and a consensus price target of $43.50.

Sarepta Therapeutics Price Performance

SRPT stock traded down $0.32 during trading on Monday, reaching $17.94. 4,062,588 shares of the company were exchanged, compared to its average volume of 6,263,534. The company has a market cap of $1.75 billion, a P/E ratio of -20.61 and a beta of 0.46. Sarepta Therapeutics has a 52-week low of $10.41 and a 52-week high of $140.97. The stock's 50 day moving average price is $17.86 and its 200 day moving average price is $48.95. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.81 and a current ratio of 2.89.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported $2.02 EPS for the quarter, topping analysts' consensus estimates of $0.89 by $1.13. The firm had revenue of $611.09 million for the quarter, compared to the consensus estimate of $530.66 million. Sarepta Therapeutics had a negative net margin of 2.34% and a negative return on equity of 1.03%. The firm's revenue was up 68.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.07 earnings per share. As a group, analysts predict that Sarepta Therapeutics will post 2.67 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sarepta Therapeutics

A number of large investors have recently bought and sold shares of SRPT. Thrivent Financial for Lutherans raised its stake in shares of Sarepta Therapeutics by 3.3% in the 2nd quarter. Thrivent Financial for Lutherans now owns 23,140 shares of the biotechnology company's stock valued at $396,000 after acquiring an additional 744 shares during the period. FORA Capital LLC raised its stake in shares of Sarepta Therapeutics by 1,442.4% in the 2nd quarter. FORA Capital LLC now owns 93,189 shares of the biotechnology company's stock valued at $1,594,000 after acquiring an additional 87,147 shares during the period. CANADA LIFE ASSURANCE Co raised its stake in shares of Sarepta Therapeutics by 2.5% in the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 71,533 shares of the biotechnology company's stock valued at $1,224,000 after acquiring an additional 1,769 shares during the period. Corient Private Wealth LLC raised its stake in shares of Sarepta Therapeutics by 75.0% in the 2nd quarter. Corient Private Wealth LLC now owns 12,530 shares of the biotechnology company's stock valued at $214,000 after acquiring an additional 5,371 shares during the period. Finally, E Fund Management Co. Ltd. raised its stake in shares of Sarepta Therapeutics by 81.4% in the 2nd quarter. E Fund Management Co. Ltd. now owns 16,525 shares of the biotechnology company's stock valued at $283,000 after acquiring an additional 7,416 shares during the period. Hedge funds and other institutional investors own 86.68% of the company's stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.